CIK 0001650648
- Non-accelerated filer
- Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 473506994
- Phone
- +1 510-505-2680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,616,428
- in 5 filings, $1.6M under 10b5-1 plans
Net −$1,616,428. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-04 | VIKING GLOBAL INVESTORS LP 10% owner | Sale | −540,000 | $19.53 | $10.5M | 4,247,914 |
| 2023-05-09 | VIKING GLOBAL INVESTORS LP 10% owner | Purchase | +850,000 | $16.00 | $13.6M | 4,787,914 |
| 2020-12-15 | VIKING GLOBAL INVESTORS LP 10% owner | Conversion | +2,004,581 | 2,004,581 | ||
| 2020-12-15 | VIKING GLOBAL INVESTORS LP 10% owner | Conversion | +833,333 | 2,837,914 | ||
| 2020-12-15 | VIKING GLOBAL INVESTORS LP 10% owner | Purchase | +1,100,000 | $23.00 | $25.3M | 3,937,914 |
| 2020-12-15 | VIKING GLOBAL INVESTORS LP 10% owner | Conversion · Series B Redeemable Convertible Preferred Stock | −2,004,581 | 0 | ||
| 2020-12-15 | VIKING GLOBAL INVESTORS LP 10% owner | Conversion · Series C Redeemable Convertible Preferred Stock | −833,333 | 0 |
Page 1 of 1 · 7 trades